nach oben

Erschienen in:

01.04.2014 | Original Article

Selection and characterization of an acid-resistant mutant of serotype O foot-and-mouth disease virus

verfasst von: Te Liang, Decheng Yang, Mengmeng Liu, Chao Sun, Fang Wang, Jingfei Wang, Haiwei Wang, Shanshan Song, Guohui Zhou, Li Yu

Erschienen in: Archives of Virology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Foot-and-mouth disease virus (FMDV) loses infectivity and immunogenicity due to its disassembly in culture environments below pH 6.8. To study the molecular basis of viral resistance to acid-induced disassembly and improve the acid stability of inactivated FMD vaccines during the manufacturing process, type O FMDV mutants with increased resistance to acid inactivation were selected, and the genes encoding their capsid proteins were sequenced. Three amino acid substitutions (VP1 N17D, VP2 D86A, and VP4 S73N) were found in all of the mutants. When these substitutions were introduced into seven infectious FMDV clones alone or combined, a single amino acid substitution in the VP1 protein, N17D, which also appears in type C FMDV acid-resistant mutants, was found to be responsible for the increased resistance to acid inactivation for type O FMDV. In addition, although viral fitness was reduced under standard culture conditions, viral growth kinetics and virulence were not significantly altered in the rescued mutant virus rN17D with the VP1 N17D substitution. Importantly, the N17D substitution could confer improved immunogenicity to the mutant virus rN17D under acidic conditions compared with its parental virus O/YS/CHA/05. These results demonstrate that the N17D substitution in VP1 is the molecular determinant of the acid-resistant phenotype in type O FMDV, indicating the potential for use of this substitution to improve the acid stability of inactivated FMD vaccines during the vaccine production process.

Acharya R, Fry E, Stuart D, Fox G, Rowlands D, Brown F (1989) The three-dimensional structure of foot-and-mouth disease virus at 2.9 Å resolution. Nature 337:709–716PubMedCrossRef

Almela MJ, González ME, Carrasco L (1991) Inhibitors of poliovirus uncoating efficiently block the early membrane permeabilization induced by virus particles. J Virol 65:2572–2577PubMedCentralPubMed

Bachrach HL (1968) Foot-and-mouth disease. Annu Rev Microbiol 22:201–244PubMedCrossRef

Baranowski E, Molina N, Núñez JI, Sobrino F, Sáiz M (2003) Recovery of infectious foot-and-mouth disease virus from suckling mice after direct inoculation with in vitro-transcribed RNA. J Virol 77:11290–11295PubMedCentralPubMedCrossRef

Baxt B (1987) Effect of lysosomotropic compounds on early events in foot-and-mouth disease virus replication. Virus Res 7:257–271PubMedCrossRef

Brown F, Cartwright B (1961) Dissociation of foot-and-mouth disease virus into its nucleic acid and protein components. Nature 192:1163–1164PubMedCrossRef

Capstick P, Garland A, Chapman W, Masters R (1967) Factors affecting the production of foot-and-mouth disease virus in deep suspension cultures of BHK 21 clone 13 cells. J Hyg 65:273–280PubMedCentralPubMedCrossRef

Carrillo EC, Giachetti C, Campos RH (1984) Effect of lysosomotropic agents on the foot-and-mouth disease virus replication. Virology 135:542–545PubMedCrossRef

Carrillo EC, Giachetti C, Campos R (1985) Early steps in FMDV replication: further analysis on the effects of chloroquine. Virology 147:118–125PubMedCrossRef

10.

Curry S, Abrams CC, Fry E, Crowther JC, Belsham GJ, Stuart DI, King A (1995) Viral RNA modulates the acid sensitivity of foot-and-mouth disease virus capsids. J Virol 69:430–438PubMedCentralPubMed

11.

Diez J, Dávila M, Escarmis C, Mateu M, Dominguez J, Perez J, Giralt E, Melero J, Domingo E (1990) Unique amino acid substitutions in the capsid proteins of foot-and-mouth disease virus from a persistent infection in cell culture. J Virol 64:5519–5528PubMedCentralPubMed

12.

Doel T, Baccarini P (1981) Thermal stability of foot-and-mouth disease virus. Arch Virol 70:21–32PubMedCrossRef

13.

Doel T, Chong W (1982) Comparative immunogenicity of 146S, 75S and 12S particles of foot-and-mouth disease virus. Arch Virol 73:185–191PubMedCrossRef

14.

Doel T (2003) FMD vaccines. Virus Res 91:81–99PubMedCrossRef

15.

Doel T (2005) Natural and vaccine induced immunity to FMD, Foot-and-mouth disease virus. Curr Top Microbiol Immunol 288:103–131PubMed

16.

Domingo E, Mateu MG, Martinez M, Dopazo J, Moya A, Sobrino F (1990) Genetic variability and antigenic diversity of foot-and-mouth disease virus. Appl Virol Res 2:233–266

17.

Domingo E, Biebricher CK, Eigen M, Holland JJ (2001) Quasispecies and RNA virus evolution: principles and consequences. Landes Bioscience, Georgetown

18.

Domingo E, Baranowski E, Escarmís C, Sobrino F (2002) Foot-and-mouth disease virus. Comp Immunol Microbiol Infect Dis 25:297–308PubMedCrossRef

19.

Domingo E, Escarmís C, Baranowski E, Ruiz-Jarabo CM, Carrillo E, Núñez JI, Sobrino F (2003) Evolution of foot-and-mouth disease virus. Virus Res 91:47–63PubMedCrossRef

20.

Domingo E, Ruiz-Jarabo C, Arias A, García-Arriaza J, Escarmís C, Sobrino F (2004) Quasispecies dynamics and evolution of foot-and-mouth disease virus. In: Sobrino F, Domingo E (eds) Foot-and-mouth disease. Current perspectives. Horizon Bioscience, Norfolk, pp 261–304CrossRef

21.

Domingo E, Martı′n V, Perales C, Grande-Pe′rez A, Garcı′a-Arriaza J, Arias A (2006) Quasispecies: concept and implications for virology. In: Domingo E (ed) Springer, Berlin, pp 51–82

22.

Ellard FM, Drew J, Blakemore WE, Stuart DI, King AM (1999) Evidence for the role of His-142 of protein 1C in the acid-induced disassembly of foot-and-mouth disease virus capsids. J Gen Virol 80:1911–1918PubMed

23.

Grubman MJ, Baxt B (2004) Foot-and-mouth disease. Clin Microbiol Rev 17:465–493PubMedCentralPubMedCrossRef

24.

Gutiérrez-Rivas M, Pulido MR, Baranowski E, Sobrino F, Sáiz M (2008) Tolerance to mutations in the foot-and-mouth disease virus integrin-binding RGD region is different in cultured cells and in vivo and depends on the capsid sequence context. J Gen Virol 89:2531–2539PubMedCrossRef

25.

Kärber G (1931) Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharmacol 162:480–483CrossRef

26.

Maree FF, Blignaut B, de Beer TA, Rieder E (2013) Analysis of SAT type foot-and-mouth disease virus capsid proteins and the identification of putative amino acid residues affecting virus stability. PLoS One 8:e61612PubMedCentralPubMedCrossRef

27.

Martín-Acebes MA, Rincón V, Armas-Portela R, Mateu MG, Sobrino F (2010) A single amino acid substitution in the capsid of foot-and-mouth disease virus can increase acid lability and confer resistance to acid-dependent uncoating inhibition. J Virol 84:2902–2912PubMedCentralPubMedCrossRef

28.

Martín-Acebes MA, Saiz JC (2011) A West Nile virus mutant with increased resistance to acid-induced inactivation. J Gen Virol 92:831–840PubMedCrossRef

29.

Martín-Acebes MA, Vázquez-Calvo Á, Rincón V, Mateu MG, Sobrino F (2011) A single amino acid substitution in the capsid of foot-and-mouth disease virus can increase acid resistance. J Virol 85:2733–2740PubMedCentralPubMedCrossRef

30.

Mateo R, Mateu MG (2007) Deterministic, compensatory mutational events in the capsid of foot-and-mouth disease virus in response to the introduction of mutations found in viruses from persistent infections. J Virol 81:1879–1887PubMedCentralPubMedCrossRef

31.

Mateo R, Luna E, Rincón V, Mateu MG (2008) Engineering viable foot-and-mouth disease viruses with increased thermostability as a step in the development of improved vaccines. J Virol 82:12232–12240PubMedCentralPubMedCrossRef

32.

Mateu M, Verdaguer N, Sobrino F, Domingo E (2004) Functional and structural aspects of the interaction of foot-and-mouth disease virus with antibodies. Foot and mouth disease: current perspectives, pp 223–260

33.

Mateu MG (1995) Antibody recognition of picornaviruses and escape from neutralization: a structural view. Virus Res 38:1–24PubMedCrossRef

34.

Mosser AG, Sgro J-Y, Rueckert RR (1994) Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions. J Virol 68:8193–8201PubMedCentralPubMed

35.

Nandi S, Suryanarayana V, Banumathi N, Sen A (1997) Biochemical characterization of FMDV A₁₀ and A₂₂ subtypes by PAGE and IEF. Comp Immunol Microbiol Infect Dis 20:95–99PubMedCrossRef

36.

Newman J, Rowlands D, Brown F (1973) A physico-chemical sub-grouping of the mammalian picornaviruses. J Gen Virol 18:171–180PubMedCrossRef

37.

Pereira H (1981) Foot-and-mouth disease. In: Gibbs EPJ (ed) Virus disease of food animals, vol 2. Academic Press, London, pp 333–363

38.

Prchla E, Kuechler E, Blaas D, Fuchs R (1994) Uncoating of human rhinovirus serotype 2 from late endosomes. J Virol 68:3713–3723PubMedCentralPubMed

39.

Rodriguez LL, Grubman MJ (2009) Foot and mouth disease virus vaccines. Vaccine 27(Suppl 4):D90–D94PubMedCrossRef

40.

Sobrino F, Domingo E (2001) Foot-and-mouth disease in Europe: FMD is economically the most important disease of farm animals. Its re-emergence in Europe is likely to have consequences that go beyond severe alterations of livestock production and trade. EMBO Rep 2:459–461PubMedCentralPubMedCrossRef

41.

Twomey T, France L, Hassard S, Burrage T, Newman J, Brown F (1995) Characterization of an acid-resistant mutant of foot-and-mouth disease virus. Virology 206:69–75PubMedCrossRef

42.

Vázquez-Calvo Á, Caridi F, Rodriguez-Pulido M, Borrego B, Sáiz M, Sobrino F, Martín-Acebes MA (2012) Modulation of foot-and-mouth disease virus pH threshold for uncoating correlates with differential sensitivity to inhibition of cellular Rab GTPases and decreases infectivity in vivo. J General Virol 93:2382–2386CrossRef

43.

van Vlijmen HW, Curry S, Schaefer M, Karplus M (1998) Titration calculations of foot-and-mouth disease virus capsids and their stabilities as a function of pH. J Mol Biol 275:295–308PubMedCrossRef

44.

Vasquez C, Denoya CD, La Torre JÈL, Palma EL (1979) Structure of foot-and-mouth disease virus capsid. Virology 97:195–200PubMedCrossRef

45.

Yang D, Tu Y, Wang H, Zhou G, Yu L (2009) Construction of infectious cDNA clone for PanAsia strain of FMDV serotype O. Chin J Prev Vet Med 31:1–5

46.

Yang D, Zhang C, Zhao L, Zhou G, Wang H, Yu L (2010) Identification of a conserved linear epitope on the VP1 protein of serotype O foot-and-mouth disease virus by neutralising monoclonal antibody 8E8. Virus Res 155:291–299PubMedCrossRef

Titel: Selection and characterization of an acid-resistant mutant of serotype O foot-and-mouth disease virus
verfasst von: Te Liang
Decheng Yang
Mengmeng Liu
Chao Sun
Fang Wang
Jingfei Wang
Haiwei Wang
Shanshan Song
Guohui Zhou
Li Yu
Publikationsdatum: 01.04.2014
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 4/2014
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-013-1872-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Inhibitory effect of doxycycline against dengue virus replication in vitro

Molecular variability of cowpea mild mottle virus infecting soybean in Brazil

Biological and genomic analysis of a PBSX-like defective phage induced from Bacillus pumilus AB94180

Discovery of a new sesquiterpenoid from Phellinus ignarius with antiviral activity against influenza virus

Engineered retroviral virus-like particles for receptor targeting